Reported 1 day ago
In June 2025, Danish biotech company Genmab A/S opened a new hub in Plainsboro, New Jersey, marking a shift towards direct commercialization of its antibody-based therapies for cancer and serious diseases. This strategic move reflects the company's goal to become an integrated global entity, enhancing control over innovation, regulatory processes, and patient outreach. With successful products like Tivdak and Epkinly, and ongoing developments in their pipeline, Genmab aims to foster long-term growth and independence in the biotech industry.
Source: YAHOO